Q 901
Alternative Names: Q-901Latest Information Update: 02 Jul 2024
At a glance
- Originator The Lead Discovery Center; The Max Planck Institute of Biochemistry
- Developer Qurient Co
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Preliminary efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 21 May 2024 Qurient Therapeutics enters into an Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute (NCI) for phase I/II trial in Small cell lung cancer (SCLC) and Solid tumours
- 21 May 2024 Qurient Therapeutics plans phase I/II trial in Small cell lung cancer (SCLC) and Solid tumours